Supported Research
-
Grant description: Beyond surgical resection, there is no effective therapy nowadays to treat FA patients that develop solid tumors, so a drug able to kill tumor cells but nontoxic for FA patients is of critical relevance. Gefitinib and afatinib candidates are approved drugs and are...
-
Oral cancer in Fanconi patients is a severe disease requiring innovative treatment and prevention measures. The potential use of FDA-approved diabetes drugs is a practical strategy for Fanconi patients for oral cancer prevention or treatment studies, once these preliminary studies are conducted. There is an...
-
Grant description: Persons with FA, as well as their family members, voice concern about being underweight and unable to build muscle mass. These concerns have an obvious physical impact, not only on the person's appearance to others and themselves and the negative impact on immune...
-
FA confers a high risk of developing leukemia at a young age, and patients with FA who develop leukemia are difficult to treat with have poor long-term outcomes. Leukemia develops as a consequence of the acquisition of genetic mutations within blood stem cells in the...
-
Head and neck cancer is a major issue for the FA population. There is no suitable preclinical model to study potential strategies for preventing or delaying squamous cell carcinoma in FA. Using a cancer-prone mouse model developed by a lab in the United Kingdom, researchers...
-
Grant description: Treatment of blood complications in FA kids using bone marrow transplantation has seen great improvement over the past decade. However, after a successful bone marrow transplantation, those kids affected with FA must now face nonblood malignancies in subsequence adolescent life which defy conventional...
-
Grant description Bone marrow transplantation has been used for 60+ years to treat >1,000,000 patients suffering from many types of blood or immune diseases, and this therapy is the best current treatment for FA patients experiencing blood problems. This procedure relies on replacing sick blood-forming...
-
Fanconi Anemia (FA) is characterized by fragile bone marrow and the inability to repair DNA damage which accumulates in repopulating stem cells, leading to marrow failure. Current treatments often involve bone marrow transplantation however the majority of patients will not have an appropriately matched sibling...
-
Fanconi anemia patients are dramatically predisposed to early-onset and aggressive head, neck, and anogenital squamous cell carcinoma (SCC). Treating Fanconi SCCs is challenging due to high-frequency recurrence and patient chemosensitivity, yielding an average survival rate of <2 years post-diagnosis. New treatment strategies are desperately needed....
-
Grant description: Low blood counts due to bone marrow failure are a common complication of Fanconi anemia (FA) which affect health and quality of life. Metformin improves blood counts in mice with FA and may protect against DNA damage. Laboratory studies suggest that Metformin may...
The Latest
News & Events
Ford loved his Mama and Daddy. He lit up anytime his Grandma, Grandpa or hospice nurse, Molly, came into the room. He loved the color blue, his stuffed animal giraffe and his puppy dog brother, Boats. He had the craziest, cutest, fluffiest hair and almost always had a binky in his mouth. When he didn’t, he was sticking out his tongue or smiling with his whole face. His nursery is decorated with moons, planets and stars. He was always bigger than the whole sky.
Czechowicz lab at Stanford Promising research needs continued support to answer the next question. A laboratory finding may need testing in more models. A screening study may need years of follow-up. An approach ready for a clinical study needs the...
How can we prevent cancer in people with FA? How can treatments become safer? At the 2026 FA Scientific Symposium in Phoenix, researchers shared progress toward answering these questions, alongside work to protect blood-forming cells and better understand the broader effects of FA. Some approaches are entering clinical studies. Others are helping researchers decide which ideas deserve further testing.